Frohning Andrea L.

Frohning Andrea L., SVP and CHRO at DENTSPLY SIRONA Inc. (XRAY), has engaged in a mix of stock awards and discretionary sales over the past two years, according to SEC Form 4 filings. The transactions show a net selling bias, with $97,894 in total sales outweighing $60,249 in acquired shares, primarily through awards. Most sales occurred in concentrated bursts, including three transactions on March 3–4, 2026, totaling $75,335—comprising a $26,294 sale, a $39,767 sale, and a $9,274 sale. Earlier disposals included a $12,347 sale in March 2025 and a $10,212 sale in August 2025. By contrast, Frohning’s acquisitions were smaller and largely tied to equity awards, such as $277 grants in January 2026 and $274 in October 2025, with no open-market purchases recorded. The activity suggests a pattern of periodic divestment, particularly in early 2026, when Frohning liquidated the bulk of reported holdings. No recent transactions indicate ongoing buying or selling as of the latest filings. All activity centers exclusively on XRAY, with no trades in other securities. The filings reflect routine equity compensation management rather than sustained accumulation, as discretionary sales consistently offset awarded shares. The absence of open-market purchases and the focus on monetizing vested awards align with a neutral-to-distributive approach to holdings in the dental products company.